1UC Stock Overview A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Cue Biopharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cue Biopharma Historical stock prices Current Share Price US$1.52 52 Week High US$2.77 52 Week Low US$0.31 Beta 1.63 1 Month Change 50.50% 3 Month Change 40.74% 1 Year Change -45.17% 3 Year Change -83.02% 5 Year Change -86.06% Change since IPO -84.54%
Recent News & Updates
Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.24 loss in 3Q 2023) Nov 17
Cue Biopharma Announces Strategic Organizational Transition Nov 15
Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting Nov 09 Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million. Sep 28
Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer Sep 11 See more updates
Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.24 loss in 3Q 2023) Nov 17
Cue Biopharma Announces Strategic Organizational Transition Nov 15
Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting Nov 09 Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million. Sep 28
Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer Sep 11
Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Aug 18
Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Aug 17
New major risk - Financial position Aug 16
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.29 loss in 2Q 2023) Aug 16 Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index
Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee Jun 10
First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023) May 15
First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023) May 10
Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
New major risk - Revenue and earnings growth Apr 10
Full year 2023 earnings released: US$1.11 loss per share (vs US$1.49 loss in FY 2022) Mar 30
New major risk - Revenue and earnings growth Mar 13
New minor risk - Market cap size Feb 18
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2022) Nov 05
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023 Nov 04
New minor risk - Market cap size Oct 04
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®? Sep 27
Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023 Sep 15
New major risk - Share price stability Aug 18
Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.37 loss in 2Q 2022) Aug 09
Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting May 26 Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million. May 11
First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.44 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$1.49 loss per share (vs US$1.41 loss in FY 2021) Mar 22
Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board Feb 17
Cue Biopharma, Inc. Announces Executive Changes Jan 24 Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding Nov 16
Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting Nov 11
Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Oct 06
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers Aug 23
Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.33 loss in 2Q 2021) Aug 06
Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees Jun 23
Insider recently bought €98k worth of stock Jun 01
U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application May 12
First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.41 loss in 1Q 2021) May 11
Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022 May 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020) Nov 10
Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT Oct 01
Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101 Sep 23
Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.38 loss in 2Q 2020) Aug 10
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC Jun 11
Cue Biopharma to Present A Corporate and Clinical Progress Update At the Upcoming Jefferies Virtual Healthcare Conference May 27
First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.48 loss in 1Q 2020) May 12
Cue Biopharma Reports Confirms Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer May 11
Cue Biopharma, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020 Mar 17
Revenue misses expectations Mar 11
Full year 2020 earnings released: US$1.56 loss per share (vs US$1.67 loss in FY 2019) Mar 11
Cue Biopharma, Inc. Announces Executive Changes Feb 26
Cue Biopharma, Inc. Appoints Dr. Matteo Levisetti as Senior Vice President of Clinical Development, Effective February 22, 2021 Feb 18
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA Feb 09
New 90-day low: €9.95 Dec 31
Independent Director recently bought €70k worth of stock Nov 26 Cue Biopharma, Inc. Extends Research Collaboration for the Development of Immuno-Stat Biologics for the Treatment of Defined Autoimmune Diseases with Merck
New 90-day low: €10.80 Nov 20
Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting Nov 10
Independent Director recently bought €129k worth of stock Oct 02
New 90-day low: €12.80 Sep 25
Cue Biopharma, Inc. Announces Appointment of Tamar Howson to Board of Directors Sep 18
New 90-day low - €15.50 Aug 26
First half earnings released Aug 10
New 90-day low - €17.90 Jul 23 Shareholder Returns 1UC DE Biotechs DE Market 7D 58.3% 6.0% 1.7% 1Y -45.2% -5.6% 9.4%
See full shareholder returns
Return vs Market: 1UC underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is 1UC's price volatile compared to industry and market? 1UC volatility 1UC Average Weekly Movement 23.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1UC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1UC's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Show more Cue Biopharma, Inc. Fundamentals Summary How do Cue Biopharma's earnings and revenue compare to its market cap? 1UC fundamental statistics Market cap €98.26m Earnings (TTM ) -€43.25m Revenue (TTM ) €9.24m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1UC income statement (TTM ) Revenue US$9.53m Cost of Revenue US$37.29m Gross Profit -US$27.76m Other Expenses US$16.85m Earnings -US$44.61m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.70 Gross Margin -291.24% Net Profit Margin -468.02% Debt/Equity Ratio 20.9%
How did 1UC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 11:33 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cue Biopharma, Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Brian Skorney Baird Zhiqiang Shu Berenberg
Show 8 more analysts 
